What changed
$TRV — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $11.9B | EPS $7.71 vs $7.08 🟢
💡 Consensus expects modest earnings growth and no multiple expansion, underestimating the durability of hard market pricing and investment income tailwinds. Our variant view: earnings will continue to beat, driving a re-rating toward peer multiples.
📉 Reward/risk: 2.12:1
🏢 Business Quality: 8/10 - Well-managed, consistent underwriting discipline, strong balance sheet, 22-year dividend growth streak.
📊 Valuation: cheap relative to peers on P/E (9.1x vs ~11x sector median), supported by strong capital generation and dividend growth.
🔮 Catalyst: Q2 2026 earnings (expected Aug 2026) confirming continued strong premium growth and margin expansion
💰 Entry: $302.65, stop $285.0, target $340.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/TRV0618